Drugs / Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)
Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06866574 | Apr 2025 → Sep 2031 expected | anal carcinoma, anogenital human papillomavirus infection, intraepithelial neoplasia | Xiamen University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06866574 ↗ |
| Modality | Vaccine | “Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)” NCT06866574 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular injection in the deltoid muscle of the upper arm” NCT06866574 ↗ |